Current Pharmaceutical Design , 24(18), 1972-1989.
Xingang Guan, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Metabolomics and lipidomics can identify substrate stress, mitochondrial bottlenecks, amino acid imbalance, redox dysregulation, and systemic drivers such as diabetes or chronic kidney disease ( This review synthesizes recent evidence on key metabolic derangementssubstrate inflexibility, mitochondrial dysfunction, BCAA accumulation, and ketone adaptationin myocardial hypertrophy, and critically examines their potential as clinically interpretable biomarker modules and therapeutic targets, while highlighting the persistent challenges in distinguishing adaptive from maladaptive remodeling and translating pathway signals into practice
no completed human clinical trials have been published
Is this real medication